BUSINESS
Nichi-Iko Pitting Allegra AG against Other Generics, Not Originator: Pres. Tamura
Nichi-Iko Pharmaceutical is stepping up its promotions for its authorized generic (AG) of the anti-allergic drug Allegra (fexofenadine), focusing on switches from other fexofenadine generics, but not the Allegra originator sold by partner Sanofi K.K. At an earnings conference on…
To read the full story
Related Article
BUSINESS
- FRONTEO to Back Biotech Startups with AI and Capital as Third Biz Leg
February 13, 2026
- Biomedix Takes Over Originator Data as Generics Face Supply, Information Challenge
February 13, 2026
- Datroway Filed for 1st-Line TNBC in Japan: Daiichi Sankyo
February 13, 2026
- Nxera Gets US$1.8 Million Early-Stage Milestone from Centessa
February 13, 2026
- Nxera Licenses GPCR Program to European VC-Backed Startup
February 13, 2026
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…





